Active Filter(s):
Details:
The MIM-728 trial is comparing the efficacy of 5% tavilermide and 1% tavilermide ophthalmic solutions to vehicle (placebo), each dosed two times a day (BID) for 12 weeks.
Lead Product(s): Tavilermide
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2020